Codexis, a developer of biocatalysts for the pharmaceutical and fine chemical industries, has appointed Pam Cheng to its board of directors.
Cheng is a 17-year veteran of Merck & Co and is currently President of MSD China, where she has direct responsibility for US$1.3bn in sales and approximately 4,000 employees, covering a wide functional scope which includes commercial, R&D, manufacturing and various business support organisations.
John Nicols, President and CEO of Codexis, said Cheng is 'exceptionally well qualified to help us continue to grow the company using the significant depth of her pharmaceutical experience and extensive industry network both in the US and Asia. We look forward to benefiting from her insight and strategic guidance.'
Cheng said: 'I am excited to join the board of Codexis, particularly at this important time for the company, as highlighted by its recent ground breaking CodeEvolver licensing agreement. Codexis has a great proven-technology foundation, and I intend to help take the company to the next level by leveraging my global experiences in the pharmaceutical industry.'
Prior to her current role, Cheng was Senior Vice President, Global Supply Chain Management for Merck in New Jersey, with overall end-to-end supply chain oversight for its human health, vaccines, and consumer care businesses globally. Before Merck, Cheng held operational roles at GAF Chemicals and UOP/Union Carbide.
